NextCell Pharma AB (“NextCell”) announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a regular inspection by the Medical Products Agency which resulted in the wholesale distribution authorization being extended for five years.
The wholesale distribution authorization allows NextCell to store and distribute the study drug, ProTrans, for use in the clinical trials.
In addition to the Medical Products Agency, the Health and Care Inspectorate (IVO) acts as supervisory authority for the NextCell operations. IVO supervises the permits regarding tissue establishment and the primary and secondary sample collection in the Bio bank. IVO performed the latest inspection in May 2018.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595